Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas

American Journal of Clinical Pathology

Volumn 142, Issue 2, 2014, Pages 173-183

  Mohanty, Sambit K ^a   Smith, Steven C ^a   Chang, Elena ^a   Luthringer, Daniel J ^a   Gown, Allen M ^b   Aron, Manju ^a   Amin, Mahul B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b PHENOPATH LABORATORIES   (United States)

Author keywords

Bladder neck; GATA3, S100P, PSMA, NKX3.1, p501S, AR, and ERG; Immunohistochemistry; Prostatic adenocarcinoma; Urothelial carcinoma

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CYTOKERATIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P63; PROTEIN S 100; TRANSCRIPTION FACTOR GATA 3; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER NECK; CLINICAL ARTICLE; FEMALE; HISTOGENESIS; HUMAN; IMMUNOREACTIVITY; MALE; PROSTATE ADENOCARCINOMA; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; AR; BLADDER; BLADDER TUMOR; CELL DIFFERENTIATION; COHORT ANALYSIS; ELECTRORETINOGRAM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; NKX3.1; P501S; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PSMA; S100P; VERY ELDERLY;

AR; BLADDER NECK; ERG; GATA3; IMMUNOHISTOCHEMISTRY; NKX3.1; P501S; PROSTATIC ADENOCARCINOMA; PSMA; S100P; UROTHELIAL CARCINOMA;

AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84907224308     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPK1OV6IMNPFGL     Document Type: Article

References (42)

1. Aihara M, Lebovitz RM, Wheeler TM, et al. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994;151:1558-1564.
2. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-477.
3. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22:88-104.
4. Alanen KA, Kuopio T, Koskinen PJ, et al. Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues. Pathol Res Pract. 1996;192:233-237.
5. Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:xiv, 648.
6. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:1081-1087.
7. Gulmann C, Paner GP, Parakh RS, et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol. 2013;44:164-172.
8. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
9. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140.
10. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13-22.
11. Aslan G, Irer B, Tuna B, et al. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract. 2006;202:93-98.
12. Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000;60:6111-6115.
13. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255.
14. Srinivasan M, Parwani AV. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn Pathol. 2011;6:67.
15. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26:5630-5637.
16. Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol. 2013;31:1866-1873.
17. Yaziji H, Eisen R, Wick M, et al. Immunohistochemistry cocktails are here to stay: Center for Medicare and Medicaid Services should revise its new reimbursement policy. Am J Clin Pathol. 2012;138:10-11.
18. Chang A, Brimo F, Montgomery EA, et al. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma. Hum Pathol. 2013;44:1563-1568.
19. Yao R, Lopez-Beltran A, Maclennan GT, et al. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 2007;27:3051-3058.
20. Zhao L, Antic T, Witten D, et al. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Am J Surg Pathol. 2013;37(12):1876-81.
21. Cimino-Mathews A, Subhawong AP, Illei PB, et al. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 2013;44:1341-1349.
22. Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.
23. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2013;38:13-22.
24. So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol. 2013;26:1365-1370.
25. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36:1472-1476.
26. Smith SC, Mohanty SK, Kunju LP, et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology. 2014;65:132-138.
27. Gandou C, Harada K, Sato Y, et al. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum Pathol. 2013;44:811-821.
28. Liu H, Shi J, Anandan V, et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136:601-609.
29. Yuan RH, Chang KT, Chen YL, et al. S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS One. 2013;8:e65501.
30. Kunju LP, Mehra R, Snyder M, et al. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol. 2006;125:675-681.
31. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
32. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47:1-16.
33. Varma M, Berney DM, Jasani B, et al. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J Clin Pathol. 2004;57:687-690.
34. Varma M, Morgan M, Jasani B, et al. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. Am J Clin Pathol. 2002;118:202-207.
35. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-9216.
36. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50:472-483.
37. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011;29:43-51.
38. Downes MR, Torlakovic EE, Aldaoud N, et al. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. J Clin Pathol. 2013;66:779-786.
39. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012;136:935-946.
40. Bhalla R, Kunju LP, Tomlins SA, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013;26:835-848.
41. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
42. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590-598.